ReviewFrontiers in immunology2025
Marine-derived L-asparaginase: unlocking marine power in anti-tumor therapeutics.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fusion Protein Technology to Enhance Pharmacological Properties of L-Asparaginases.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-asparaginase, a critical enzyme for cancer therapy, has been primarily produced by microbes. Researches are being conducted to identify better stabilizing, low immunogenicity and highly active alternative sources has focused on marine microorganisms. Marine-derived L-asparaginase is a promising candidate due to its unique characteristics and broad application potential. This review discusses the molecular structure, production-related genes, and the search for marine microbial sources of L-asparaginase production. Roles of L-asparaginase in cancer metabolism including asparagine depletion, apoptosis induction, autophagy and immunity are also detailed. Clinical studies with L-asparaginase in the treatment of pediatric and adult acute lymphoblastic leukemia is described, with indications for solid tumors. Also, combination therapy using L-asparaginase such as chemotherapy, targeted therapy, and immunotherapy has been explored to enhance therapeutic effects. The discovery of marine-derived L-asparaginase variants with improved properties holds great potential for expanding the utility of this enzyme across multiple sectors, unlocking the marine power in cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.